Press Releases

New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
November 13, 2023
Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 8, 2023
First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer
November 7, 2023
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population
November 6, 2023
Verastem Oncology Strengthens Executive Leadership Team with Key Appointments
October 26, 2023
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2023
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer
October 14, 2023
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 6, 2023
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
September 28, 2023
Verastem Oncology to Participate in Upcoming Investor Conferences
September 5, 2023
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
August 28, 2023
Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 8, 2023
Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
July 11, 2023
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2023
Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
July 5, 2023
Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants
June 16, 2023
Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 15, 2023
Verastem Oncology Announces Reverse Stock Split
May 31, 2023
Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
May 25, 2023
Verastem Oncology Appoints Karin Tollefson, PharmD, to Board of Directors
May 16, 2023
Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 9, 2023
Verastem Oncology to Participate in Upcoming Investor Conferences
May 1, 2023
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting
April 26, 2023
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
April 18, 2023
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 6, 2023
New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
March 15, 2023
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
March 14, 2023
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
February 2, 2023
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
January 24, 2023
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
January 24, 2023
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 18, 2023

E-mail Alerts

You may automatically receive Verastem Oncology financial information by e-mail. To choose your options for e-mail notification, please enter your e-mail address below and click Submit.

Investor Contact

getty
Dan Calkins

Investor Relations
781-469-1694
dcalkins@verastem.com

Ryan Porter

Argot Partners
+1 212-600-1902
ryan.porter@argotpartners.com

Investor Kit
img